- Home
- PED vs NRXP Comparison
PED vs NRXP Comparison
Compare PED & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PED | NRXP |
|---|---|---|
| Founded | N/A | 2015 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 62.2M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | PED | NRXP |
|---|---|---|
| Price | $0.64 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $1.50 | ★ $30.67 |
| AVG Volume (30 Days) | 116.2K | ★ 501.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,553,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $305.89 | $847.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 28.49 | N/A |
| 52 Week Low | $0.43 | $1.58 |
| 52 Week High | $0.82 | $3.84 |
Technical Indicators
Market Signals| Indicator | PED | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 63.72 | 40.54 |
| Support Level | $0.58 | $1.73 |
| Resistance Level | $0.64 | $1.86 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 79.22 | 28.64 |
Price Performance
Historical ComparisonAbout PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.